Growth Metrics

Castle Biosciences (CSTL) Non-Current Deferred Tax Liability (2020 - 2025)

Historic Non-Current Deferred Tax Liability for Castle Biosciences (CSTL) over the last 6 years, with Q3 2025 value amounting to $3.2 million.

  • Castle Biosciences' Non-Current Deferred Tax Liability fell 2317.54% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 2317.54%. This contributed to the annual value of $1.6 million for FY2024, which is 9348.79% down from last year.
  • Latest data reveals that Castle Biosciences reported Non-Current Deferred Tax Liability of $3.2 million as of Q3 2025, which was down 2317.54% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Non-Current Deferred Tax Liability registered a high of $27.1 million during Q4 2022, and its lowest value of $206000.0 during Q1 2024.
  • Its 5-year average for Non-Current Deferred Tax Liability is $5.9 million, with a median of $837000.0 in 2025.
  • Over the last 5 years, Castle Biosciences' Non-Current Deferred Tax Liability had its largest YoY gain of 85691.61% in 2024, and its largest YoY loss of 9348.79% in 2024.
  • Quarter analysis of 5 years shows Castle Biosciences' Non-Current Deferred Tax Liability stood at $19.6 million in 2021, then skyrocketed by 38.56% to $27.1 million in 2022, then fell by 9.0% to $24.7 million in 2023, then plummeted by 93.49% to $1.6 million in 2024, then skyrocketed by 101.74% to $3.2 million in 2025.
  • Its Non-Current Deferred Tax Liability was $3.2 million in Q3 2025, compared to $3.1 million in Q2 2025 and $837000.0 in Q1 2025.